InChI Key,Compound ID,Uniprot,Target,E3 ligase,Smiles,DC50 (nM),Dmax (%),Assay (DC50/Dmax),Percent degradation (%),Assay (Percent degradation),Article DOI,Molecular Weight,Exact Mass,logP,logS,Heavy Atom Count,Ring Count,Hydrogen Bond Acceptor Count,Hydrogen Bond Donor Count,Rotatable Bond Count,Topological Polar Surface Area,Molecular Formula,InChI,cid,cmpdname,cmpdsynonym,mw,mf,polararea,complexity,xlogp,heavycnt,hbonddonor,hbondacc,rotbonds,inchi,isosmiles,iupacname,meshheadings,annothits,annothitcnt,aids,cidcdate,sidsrcname,depcatg,annotation
AMOFJSISJOOLNX-OUKQBFOZSA-N,236,P15056,BRAF,CRBN,COC1=CC(OC)=C(/C=C/S(=O)(=O)CC2=CC=C(OC)C(NCC(=O)NCC(=O)NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)=C2)C(OC)=C1,NA,NA,NA,71.7/81,% B-Raf degradation in MCF-7 cells after 24 h treatment at 5000/10000 nM,10.1016/j.bioorg.2019.03.035,763.782,763.2159426,2.36,-4.85,54,5,13,4,15,224.84,C36H37N5O12S,"InChI=1S/C36H37N5O12S/c1-50-21-15-28(52-3)22(29(16-21)53-4)12-13-54(48,49)19-20-8-10-27(51-2)25(14-20)37-17-31(43)38-18-32(44)39-24-7-5-6-23-33(24)36(47)41(35(23)46)26-9-11-30(42)40-34(26)45/h5-8,10,12-16,26,37H,9,11,17-19H2,1-4H3,(H,38,43)(H,39,44)(H,40,42,45)/b13-12+",138319681,PROTAC B-Raf degrader 1,PROTAC B-Raf degrader 1|AKOS037653384|HY-111758|CS-0090791|2364367-27-9,763.8,C36H37N5O12S,233,1540,2,54,4,13,15,"InChI=1S/C36H37N5O12S/c1-50-21-15-28(52-3)22(29(16-21)53-4)12-13-54(48,49)19-20-8-10-27(51-2)25(14-20)37-17-31(43)38-18-32(44)39-24-7-5-6-23-33(24)36(47)41(35(23)46)26-9-11-30(42)40-34(26)45/h5-8,10,12-16,26,37H,9,11,17-19H2,1-4H3,(H,38,43)(H,39,44)(H,40,42,45)/b13-12+",COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)NCC(=O)NC3=CC=CC4=C3C(=O)N(C4=O)C5CCC(=O)NC5=O,"N-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]-2-oxoethyl]-2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetamide",NULL,NULL,NA,NULL,20190513,A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|BenchChem|Chem-Space.com Database|MedChemexpress MCE|MolPort|TargetMol (Target Molecule Corp.),Chemical Vendors|Legacy Depositors,NULL
BJFBRLAWLPZOMJ-QHVFGHLPSA-N,1319,P62942,FKBP12 F36V,CRBN,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC=C1OCC(=O)NCCCCCCOC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)C1=CC(OC)=C(OC)C(OC)=C1,NA,NA,NA,NA,NA,10.1038/s41589-018-0021-8,1049.184,1048.468117,5.84,-6.51,76,7,15,2,26,223.87,C57H68N4O15,"InChI=1S/C57H68N4O15/c1-7-37(36-32-47(71-4)52(73-6)48(33-36)72-5)54(65)60-29-14-12-19-41(60)57(68)76-43(25-22-35-23-26-44(69-2)46(31-35)70-3)38-17-10-11-20-42(38)75-34-50(63)58-28-13-8-9-15-30-74-45-21-16-18-39-51(45)56(67)61(55(39)66)40-24-27-49(62)59-53(40)64/h10-11,16-18,20-21,23,26,31-33,37,40-41,43H,7-9,12-15,19,22,24-25,27-30,34H2,1-6H3,(H,58,63)(H,59,62,64)/t37-,40?,41-,43+/m0/s1",124187630,FKBP12 PROTAC dTAG-13,"FKBP12 PROTAC dTAG-13|dTAG-13|2064175-41-1|CHEMBL4586585|SCHEMBL18376186|GTPL10533|AKOS037653459|HY-114421|CS-0085058|(2S)-(1R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)amino)-2-oxoethoxy)phenyl)propyl 1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate|[(1R)-3-(3,4-dimethoxyphenyl)-1-[2-[2-[6-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyhexylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]",1049.2,C57H68N4O15,224,1930,7.4,76,2,15,27,"InChI=1S/C57H68N4O15/c1-7-37(36-32-47(71-4)52(73-6)48(33-36)72-5)54(65)60-29-14-12-19-41(60)57(68)76-43(25-22-35-23-26-44(69-2)46(31-35)70-3)38-17-10-11-20-42(38)75-34-50(63)58-28-13-8-9-15-30-74-45-21-16-18-39-51(45)56(67)61(55(39)66)40-24-27-49(62)59-53(40)64/h10-11,16-18,20-21,23,26,31-33,37,40-41,43H,7-9,12-15,19,22,24-25,27-30,34H2,1-6H3,(H,58,63)(H,59,62,64)/t37-,40?,41-,43+/m0/s1",CC[C@@H](C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCC3=CC(=C(C=C3)OC)OC)C4=CC=CC=C4OCC(=O)NCCCCCCOC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O,"[(1R)-3-(3,4-dimethoxyphenyl)-1-[2-[2-[6-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyhexylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate",NULL,Literature|Patents,2,NULL,20170218,AbaChemScene|AKos Consulting & Solutions|BenchChem|Chem-Space.com Database|ChEMBL|Chemenu Inc.|eNovation Chemicals|Google Patents|IUPHAR/BPS Guide to PHARMACOLOGY|MedChemexpress MCE|MolPort|Nature Chemical Biology|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol (Target Molecule Corp.)|Tocris Bioscience,Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development,NULL
BORXNUWYWZOREQ-UHFFFAOYSA-N,500,Q07820,MCL1,CRBN,O=C(CCCCC(=O)NCCN1C(=O)C2=CC=CC3=C(SC4=CC=C(Br)C=C4)C=CC(=C23)C1=O)NCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,700,NA,Degradation of MCL1 in HeLa cells after 12 h treatment,NA,NA,10.1021/acs.jmedchem.9b00919,909.86,908.2202955,5.1,-5.88,61,7,10,4,19,191.16,C45H45BrN6O8S,"InChI=1S/C45H45BrN6O8S/c46-27-15-17-28(18-16-27)61-35-21-19-32-39-29(35)9-7-10-30(39)42(57)51(43(32)58)26-25-49-37(54)14-4-3-13-36(53)48-24-6-2-1-5-23-47-33-12-8-11-31-40(33)45(60)52(44(31)59)34-20-22-38(55)50-41(34)56/h7-12,15-19,21,34,47H,1-6,13-14,20,22-26H2,(H,48,53)(H,49,54)(H,50,55,56)",139035048,PROTAC Mcl1 degrader-1,"PROTAC Mcl1 degrader-1|CHEMBL4460727|2163793-38-0|Mcl-1 Degrader C3|BDBM50505351|HY-125877|CS-0102617|N1-(2-(6-((4-Bromophenyl)thio)-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl)-N6-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)adipamide",909.8,C45H45BrN6O8S,217,1660,6,61,4,10,19,"InChI=1S/C45H45BrN6O8S/c46-27-15-17-28(18-16-27)61-35-21-19-32-39-29(35)9-7-10-30(39)42(57)51(43(32)58)26-25-49-37(54)14-4-3-13-36(53)48-24-6-2-1-5-23-47-33-12-8-11-31-40(33)45(60)52(44(31)59)34-20-22-38(55)50-41(34)56/h7-12,15-19,21,34,47H,1-6,13-14,20,22-26H2,(H,48,53)(H,49,54)(H,50,55,56)",C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCCNC(=O)CCCCC(=O)NCCN4C(=O)C5=C6C(=C(C=C5)SC7=CC=C(C=C7)Br)C=CC=C6C4=O,"N'-[2-[6-(4-bromophenyl)sulfanyl-1,3-dioxobenzo[de]isoquinolin-2-yl]ethyl]-N-[6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexyl]hexanediamide",NULL,Classification,1,NULL,20190930,A2B Chem|AA BLOCKS|AbaChemScene|BindingDB|BLD Pharm|Chem-Space.com Database|ChEMBL|MedChemexpress MCE|MolPort|TargetMol (Target Molecule Corp.)|THE BioTek,Chemical Vendors|Curation Efforts|Legacy Depositors|Research and Development,NULL
BORXNUWYWZOREQ-UHFFFAOYSA-N,500,Q16548,BCL2,CRBN,O=C(CCCCC(=O)NCCN1C(=O)C2=CC=CC3=C(SC4=CC=C(Br)C=C4)C=CC(=C23)C1=O)NCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,NA,NA,NA,NA,NA,10.1021/acs.jmedchem.9b00919,909.86,908.2202955,5.1,-5.88,61,7,10,4,19,191.16,C45H45BrN6O8S,"InChI=1S/C45H45BrN6O8S/c46-27-15-17-28(18-16-27)61-35-21-19-32-39-29(35)9-7-10-30(39)42(57)51(43(32)58)26-25-49-37(54)14-4-3-13-36(53)48-24-6-2-1-5-23-47-33-12-8-11-31-40(33)45(60)52(44(31)59)34-20-22-38(55)50-41(34)56/h7-12,15-19,21,34,47H,1-6,13-14,20,22-26H2,(H,48,53)(H,49,54)(H,50,55,56)",139035048,PROTAC Mcl1 degrader-1,"PROTAC Mcl1 degrader-1|CHEMBL4460727|2163793-38-0|Mcl-1 Degrader C3|BDBM50505351|HY-125877|CS-0102617|N1-(2-(6-((4-Bromophenyl)thio)-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl)-N6-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)adipamide",909.8,C45H45BrN6O8S,217,1660,6,61,4,10,19,"InChI=1S/C45H45BrN6O8S/c46-27-15-17-28(18-16-27)61-35-21-19-32-39-29(35)9-7-10-30(39)42(57)51(43(32)58)26-25-49-37(54)14-4-3-13-36(53)48-24-6-2-1-5-23-47-33-12-8-11-31-40(33)45(60)52(44(31)59)34-20-22-38(55)50-41(34)56/h7-12,15-19,21,34,47H,1-6,13-14,20,22-26H2,(H,48,53)(H,49,54)(H,50,55,56)",C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCCNC(=O)CCCCC(=O)NCCN4C(=O)C5=C6C(=C(C=C5)SC7=CC=C(C=C7)Br)C=CC=C6C4=O,"N'-[2-[6-(4-bromophenyl)sulfanyl-1,3-dioxobenzo[de]isoquinolin-2-yl]ethyl]-N-[6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexyl]hexanediamide",NULL,Classification,1,NULL,20190930,A2B Chem|AA BLOCKS|AbaChemScene|BindingDB|BLD Pharm|Chem-Space.com Database|ChEMBL|MedChemexpress MCE|MolPort|TargetMol (Target Molecule Corp.)|THE BioTek,Chemical Vendors|Curation Efforts|Legacy Depositors|Research and Development,NULL
BRYMZSSAIDEFEM-UHFFFAOYSA-N,610,P50750,CDK9,CRBN,O=C(CCC(=O)N1CCN(CC2=CC=C(NC(=O)C3=C(NC4=NC=NC5=C4C=C[NH]5)C=N[NH]3)C=C2)CC1)NCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,33,NA,Degradation of CDK9 in PC-3 cells after 24 h treatment,NA,NA,10.1016/j.ejmech.2019.111952,815.852,815.3251907,2.19,-4.06,60,8,13,7,14,259.61,C40H41N13O7,"InChI=1S/C40H41N13O7/c54-30(42-15-14-41-27-3-1-2-25-33(27)40(60)53(39(25)59)29-8-9-31(55)49-37(29)57)10-11-32(56)52-18-16-51(17-19-52)21-23-4-6-24(7-5-23)47-38(58)34-28(20-46-50-34)48-36-26-12-13-43-35(26)44-22-45-36/h1-7,12-13,20,22,29,41H,8-11,14-19,21H2,(H,42,54)(H,46,50)(H,47,58)(H,49,55,57)(H2,43,44,45,48)",145925673,PROTAC CDK2/9 Degrader-1,PROTAC CDK2/9 Degrader-1|CHEMBL4642944|BDBM50537765|HY-130709|CS-0112136,815.8,C40H41N13O7,260,1620,1.3,60,7,13,14,"InChI=1S/C40H41N13O7/c54-30(42-15-14-41-27-3-1-2-25-33(27)40(60)53(39(25)59)29-8-9-31(55)49-37(29)57)10-11-32(56)52-18-16-51(17-19-52)21-23-4-6-24(7-5-23)47-38(58)34-28(20-46-50-34)48-36-26-12-13-43-35(26)44-22-45-36/h1-7,12-13,20,22,29,41H,8-11,14-19,21H2,(H,42,54)(H,46,50)(H,47,58)(H,49,55,57)(H2,43,44,45,48)",C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCNC(=O)CCC(=O)N4CCN(CC4)CC5=CC=C(C=C5)NC(=O)C6=C(C=NN6)NC7=NC=NC8=C7C=CN8,"N-[4-[[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethylamino]-4-oxobutanoyl]piperazin-1-yl]methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide",NULL,Classification,1,NULL,20200220,AbaChemScene|BindingDB|ChEMBL|MedChemexpress MCE|MolPort,Chemical Vendors|Curation Efforts|Research and Development,NULL
BRYMZSSAIDEFEM-UHFFFAOYSA-N,610,P24941,CDK2,CRBN,O=C(CCC(=O)N1CCN(CC2=CC=C(NC(=O)C3=C(NC4=NC=NC5=C4C=C[NH]5)C=N[NH]3)C=C2)CC1)NCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,62,NA,Degradation of CDK2 in PC-3 cells after 24 h treatment,NA,NA,10.1016/j.ejmech.2019.111952,815.852,815.3251907,2.19,-4.06,60,8,13,7,14,259.61,C40H41N13O7,"InChI=1S/C40H41N13O7/c54-30(42-15-14-41-27-3-1-2-25-33(27)40(60)53(39(25)59)29-8-9-31(55)49-37(29)57)10-11-32(56)52-18-16-51(17-19-52)21-23-4-6-24(7-5-23)47-38(58)34-28(20-46-50-34)48-36-26-12-13-43-35(26)44-22-45-36/h1-7,12-13,20,22,29,41H,8-11,14-19,21H2,(H,42,54)(H,46,50)(H,47,58)(H,49,55,57)(H2,43,44,45,48)",145925673,PROTAC CDK2/9 Degrader-1,PROTAC CDK2/9 Degrader-1|CHEMBL4642944|BDBM50537765|HY-130709|CS-0112136,815.8,C40H41N13O7,260,1620,1.3,60,7,13,14,"InChI=1S/C40H41N13O7/c54-30(42-15-14-41-27-3-1-2-25-33(27)40(60)53(39(25)59)29-8-9-31(55)49-37(29)57)10-11-32(56)52-18-16-51(17-19-52)21-23-4-6-24(7-5-23)47-38(58)34-28(20-46-50-34)48-36-26-12-13-43-35(26)44-22-45-36/h1-7,12-13,20,22,29,41H,8-11,14-19,21H2,(H,42,54)(H,46,50)(H,47,58)(H,49,55,57)(H2,43,44,45,48)",C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCNC(=O)CCC(=O)N4CCN(CC4)CC5=CC=C(C=C5)NC(=O)C6=C(C=NN6)NC7=NC=NC8=C7C=CN8,"N-[4-[[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethylamino]-4-oxobutanoyl]piperazin-1-yl]methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide",NULL,Classification,1,NULL,20200220,AbaChemScene|BindingDB|ChEMBL|MedChemexpress MCE|MolPort,Chemical Vendors|Curation Efforts|Research and Development,NULL
BRZGXSNAXRPPFI-UHFFFAOYSA-N,978,O43353,RIPK2,CRBN,CC(C)(C)S(=O)(=O)C1=CC2=C(NC3=CC=C4SC=NC4=C3)C=CN=C2C=C1OCCOCCOCCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,2.5,NA,Degradation of RIPK2 in THP-1 cells after 18 h treatment,NA,NA,10.1038/s42003-020-0868-6,889.022,888.2822484,4.12,-5.73,62,7,15,3,20,213.68,C43H48N6O11S2,"InChI=1S/C43H48N6O11S2/c1-43(2,3)62(54,55)38-22-29-32(46-27-7-9-37-34(21-27)45-26-61-37)11-12-44-33(29)23-36(38)60-20-19-58-16-15-56-13-14-57-17-18-59-25-40(51)47-31-6-4-5-28-30(31)24-49(42(28)53)35-8-10-39(50)48-41(35)52/h4-7,9,11-12,21-23,26,35H,8,10,13-20,24-25H2,1-3H3,(H,44,46)(H,47,51)(H,48,50,52)",126696039,PROTAC RIPK degrader-6,PROTAC RIPK degrader-6|SCHEMBL18640013|HY-111870|CS-0093291|2089205-64-9|S1C=NC2=C1C=CC(=C2)NC1=CC=NC2=CC(=C(C=C12)S(=O)(=O)C(C)(C)C)OCCOCCOCCOCCOCC(=O)NC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O,889,C43H48N6O11S2,250,1650,3,62,3,15,21,"InChI=1S/C43H48N6O11S2/c1-43(2,3)62(54,55)38-22-29-32(46-27-7-9-37-34(21-27)45-26-61-37)11-12-44-33(29)23-36(38)60-20-19-58-16-15-56-13-14-57-17-18-59-25-40(51)47-31-6-4-5-28-30(31)24-49(42(28)53)35-8-10-39(50)48-41(35)52/h4-7,9,11-12,21-23,26,35H,8,10,13-20,24-25H2,1-3H3,(H,44,46)(H,47,51)(H,48,50,52)",CC(C)(C)S(=O)(=O)C1=CC2=C(C=CN=C2C=C1OCCOCCOCCOCCOCC(=O)NC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O)NC6=CC7=C(C=C6)SC=N7,"2-[2-[2-[2-[2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]acetamide",NULL,Patents,1,NULL,20170422,A2B Chem|AA BLOCKS|AbaChemScene|BenchChem|Google Patents|MedChemexpress MCE|MolPort|SureChEMBL,Chemical Vendors|Curation Efforts|Research and Development,NULL
CJIXMPCTSMEQPG-UHFFFAOYSA-N,1266,Q9NZQ7,PD-L1,CRBN,CC1=C(COC2=CC(OCC3=CC=CC(C#N)=C3)=C(CN3CCCCC3C(=O)N3CCN(C(=O)CCCC(=O)NC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)C=C2Cl)C=CC=C1C1=CC=C2OCCOC2=C1,NA,NA,NA,NA,NA,10.1016/j.ejmech.2020.112377,1076.604,1075.388283,5.58,-5.15,78,10,13,2,16,217.22,C59H58ClN7O11,"InChI=1S/C59H58ClN7O11/c1-36-40(10-5-11-42(36)39-17-19-48-51(30-39)76-27-26-75-48)35-78-50-31-49(77-34-38-9-4-8-37(28-38)32-61)41(29-44(50)60)33-66-21-3-2-14-47(66)58(73)65-24-22-64(23-25-65)54(70)16-7-15-52(68)62-45-13-6-12-43-55(45)59(74)67(57(43)72)46-18-20-53(69)63-56(46)71/h4-6,8-13,17,19,28-31,46-47H,2-3,7,14-16,18,20-27,33-35H2,1H3,(H,62,68)(H,63,69,71)",146673162,PROTAC PD-1/PD-L1 degrader-1,PROTAC PD-1/PD-L1 degrader-1|HY-131183|CS-0130198,1076.6,C59H58ClN7O11,217,2220,6.3,78,2,13,16,"InChI=1S/C59H58ClN7O11/c1-36-40(10-5-11-42(36)39-17-19-48-51(30-39)76-27-26-75-48)35-78-50-31-49(77-34-38-9-4-8-37(28-38)32-61)41(29-44(50)60)33-66-21-3-2-14-47(66)58(73)65-24-22-64(23-25-65)54(70)16-7-15-52(68)62-45-13-6-12-43-55(45)59(74)67(57(43)72)46-18-20-53(69)63-56(46)71/h4-6,8-13,17,19,28-31,46-47H,2-3,7,14-16,18,20-27,33-35H2,1H3,(H,62,68)(H,63,69,71)",CC1=C(C=CC=C1C2=CC3=C(C=C2)OCCO3)COC4=C(C=C(C(=C4)OCC5=CC(=CC=C5)C#N)CN6CCCCC6C(=O)N7CCN(CC7)C(=O)CCCC(=O)NC8=CC=CC9=C8C(=O)N(C9=O)C1CCC(=O)NC1=O)Cl,"5-[4-[1-[[5-chloro-2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carbonyl]piperazin-1-yl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]-5-oxopentanamide",NULL,NULL,0,NULL,20200702,AbaChemScene|MedChemexpress MCE,Chemical Vendors,NULL
CQSOTYMFUWTIIR-HUSBZTEESA-N,934,O75530,EED,VHL,CC1=NC(CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1C1=CN=C(NCC2=C(F)C=CC3=C2CCO3)N2C=NN=C12,NA,NA,NA,NA,NA,10.1016/j.chembiol.2019.11.004,960.15,959.4276278,4.34,-6.03,69,8,14,5,18,217.96,C50H58FN11O6S,"InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1",145925664,PROTAC EED degrader-2,PROTAC EED degrader-2|HY-130615|CS-0109486,960.1,C50H58FN11O6S,246,1730,5.7,69,5,14,19,"InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1",CC1=C(C=CC(=N1)CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@@H](C[C@H]2C(=O)NCC3=CC=C(C=C3)C4=C(N=CS4)C)O)C(C)(C)C)C5=CN=C(N6C5=NN=C6)NCC7=C(C=CC8=C7CCO8)F,"(2S,4R)-1-[(2S)-2-[5-[3-[5-[5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl]-6-methylpyridin-2-yl]propanoylamino]pentanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,NULL,0,NULL,20200220,AbaChemScene|MedChemexpress MCE,Chemical Vendors,NULL
CQSOTYMFUWTIIR-HUSBZTEESA-N,934,Q15022,SUZ12,VHL,CC1=NC(CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1C1=CN=C(NCC2=C(F)C=CC3=C2CCO3)N2C=NN=C12,NA,NA,NA,NA,NA,10.1016/j.chembiol.2019.11.004,960.15,959.4276278,4.34,-6.03,69,8,14,5,18,217.96,C50H58FN11O6S,"InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1",145925664,PROTAC EED degrader-2,PROTAC EED degrader-2|HY-130615|CS-0109486,960.1,C50H58FN11O6S,246,1730,5.7,69,5,14,19,"InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1",CC1=C(C=CC(=N1)CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@@H](C[C@H]2C(=O)NCC3=CC=C(C=C3)C4=C(N=CS4)C)O)C(C)(C)C)C5=CN=C(N6C5=NN=C6)NCC7=C(C=CC8=C7CCO8)F,"(2S,4R)-1-[(2S)-2-[5-[3-[5-[5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl]-6-methylpyridin-2-yl]propanoylamino]pentanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,NULL,0,NULL,20200220,AbaChemScene|MedChemexpress MCE,Chemical Vendors,NULL
CQSOTYMFUWTIIR-HUSBZTEESA-N,934,Q15910,EZH2,VHL,CC1=NC(CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1C1=CN=C(NCC2=C(F)C=CC3=C2CCO3)N2C=NN=C12,NA,NA,NA,NA,NA,10.1016/j.chembiol.2019.11.004,960.15,959.4276278,4.34,-6.03,69,8,14,5,18,217.96,C50H58FN11O6S,"InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1",145925664,PROTAC EED degrader-2,PROTAC EED degrader-2|HY-130615|CS-0109486,960.1,C50H58FN11O6S,246,1730,5.7,69,5,14,19,"InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1",CC1=C(C=CC(=N1)CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@@H](C[C@H]2C(=O)NCC3=CC=C(C=C3)C4=C(N=CS4)C)O)C(C)(C)C)C5=CN=C(N6C5=NN=C6)NCC7=C(C=CC8=C7CCO8)F,"(2S,4R)-1-[(2S)-2-[5-[3-[5-[5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl]-6-methylpyridin-2-yl]propanoylamino]pentanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,NULL,0,NULL,20200220,AbaChemScene|MedChemexpress MCE,Chemical Vendors,NULL
DCPKSVYPNGBDSB-UHFFFAOYSA-N,737,P25440,BRD2,CRBN,COC1=CC=CC=C1S(=O)(=O)NC1=CC=C2C3=C(C=C(CCC(=O)NCCCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C13)C(=O)N2C,NA,NA,NA,NA,NA,10.1016/j.bmc.2019.115181,766.833,766.2420978,3.44,-4.95,55,7,10,4,14,200.39,C39H38N6O9S,"InChI=1S/C39H38N6O9S/c1-44-28-14-13-26(43-55(52,53)31-11-4-3-10-30(31)54-2)24-20-22(21-25(34(24)28)37(44)49)12-16-32(46)41-19-6-5-18-40-27-9-7-8-23-35(27)39(51)45(38(23)50)29-15-17-33(47)42-36(29)48/h3-4,7-11,13-14,20-21,29,40,43H,5-6,12,15-19H2,1-2H3,(H,41,46)(H,42,47,48)",145712396,PROTAC BRD2/BRD4 degrader-1,PROTAC BRD2/BRD4 degrader-1|CHEMBL4633483|HY-130612|CS-0109474,766.8,C39H38N6O9S,209,1620,3.4,55,4,11,14,"InChI=1S/C39H38N6O9S/c1-44-28-14-13-26(43-55(52,53)31-11-4-3-10-30(31)54-2)24-20-22(21-25(34(24)28)37(44)49)12-16-32(46)41-19-6-5-18-40-27-9-7-8-23-35(27)39(51)45(38(23)50)29-15-17-33(47)42-36(29)48/h3-4,7-11,13-14,20-21,29,40,43H,5-6,12,15-19H2,1-2H3,(H,41,46)(H,42,47,48)",CN1C2=C3C(=CC(=CC3=C(C=C2)NS(=O)(=O)C4=CC=CC=C4OC)CCC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O)C1=O,"N-[4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butyl]-3-[6-[(2-methoxyphenyl)sulfonylamino]-1-methyl-2-oxobenzo[cd]indol-4-yl]propanamide",NULL,Classification|Patents,2,NULL,20191231,AbaChemScene|ChEMBL|MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,NULL
DCPKSVYPNGBDSB-UHFFFAOYSA-N,737,Q15059,BRD3,CRBN,COC1=CC=CC=C1S(=O)(=O)NC1=CC=C2C3=C(C=C(CCC(=O)NCCCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C13)C(=O)N2C,NA,NA,NA,NA,NA,10.1016/j.bmc.2019.115181,766.833,766.2420978,3.44,-4.95,55,7,10,4,14,200.39,C39H38N6O9S,"InChI=1S/C39H38N6O9S/c1-44-28-14-13-26(43-55(52,53)31-11-4-3-10-30(31)54-2)24-20-22(21-25(34(24)28)37(44)49)12-16-32(46)41-19-6-5-18-40-27-9-7-8-23-35(27)39(51)45(38(23)50)29-15-17-33(47)42-36(29)48/h3-4,7-11,13-14,20-21,29,40,43H,5-6,12,15-19H2,1-2H3,(H,41,46)(H,42,47,48)",145712396,PROTAC BRD2/BRD4 degrader-1,PROTAC BRD2/BRD4 degrader-1|CHEMBL4633483|HY-130612|CS-0109474,766.8,C39H38N6O9S,209,1620,3.4,55,4,11,14,"InChI=1S/C39H38N6O9S/c1-44-28-14-13-26(43-55(52,53)31-11-4-3-10-30(31)54-2)24-20-22(21-25(34(24)28)37(44)49)12-16-32(46)41-19-6-5-18-40-27-9-7-8-23-35(27)39(51)45(38(23)50)29-15-17-33(47)42-36(29)48/h3-4,7-11,13-14,20-21,29,40,43H,5-6,12,15-19H2,1-2H3,(H,41,46)(H,42,47,48)",CN1C2=C3C(=CC(=CC3=C(C=C2)NS(=O)(=O)C4=CC=CC=C4OC)CCC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O)C1=O,"N-[4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butyl]-3-[6-[(2-methoxyphenyl)sulfonylamino]-1-methyl-2-oxobenzo[cd]indol-4-yl]propanamide",NULL,Classification|Patents,2,NULL,20191231,AbaChemScene|ChEMBL|MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,NULL
DCPKSVYPNGBDSB-UHFFFAOYSA-N,737,O60885,BRD4,CRBN,COC1=CC=CC=C1S(=O)(=O)NC1=CC=C2C3=C(C=C(CCC(=O)NCCCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C13)C(=O)N2C,NA,NA,NA,NA,NA,10.1016/j.bmc.2019.115181,766.833,766.2420978,3.44,-4.95,55,7,10,4,14,200.39,C39H38N6O9S,"InChI=1S/C39H38N6O9S/c1-44-28-14-13-26(43-55(52,53)31-11-4-3-10-30(31)54-2)24-20-22(21-25(34(24)28)37(44)49)12-16-32(46)41-19-6-5-18-40-27-9-7-8-23-35(27)39(51)45(38(23)50)29-15-17-33(47)42-36(29)48/h3-4,7-11,13-14,20-21,29,40,43H,5-6,12,15-19H2,1-2H3,(H,41,46)(H,42,47,48)",145712396,PROTAC BRD2/BRD4 degrader-1,PROTAC BRD2/BRD4 degrader-1|CHEMBL4633483|HY-130612|CS-0109474,766.8,C39H38N6O9S,209,1620,3.4,55,4,11,14,"InChI=1S/C39H38N6O9S/c1-44-28-14-13-26(43-55(52,53)31-11-4-3-10-30(31)54-2)24-20-22(21-25(34(24)28)37(44)49)12-16-32(46)41-19-6-5-18-40-27-9-7-8-23-35(27)39(51)45(38(23)50)29-15-17-33(47)42-36(29)48/h3-4,7-11,13-14,20-21,29,40,43H,5-6,12,15-19H2,1-2H3,(H,41,46)(H,42,47,48)",CN1C2=C3C(=CC(=CC3=C(C=C2)NS(=O)(=O)C4=CC=CC=C4OC)CCC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O)C1=O,"N-[4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butyl]-3-[6-[(2-methoxyphenyl)sulfonylamino]-1-methyl-2-oxobenzo[cd]indol-4-yl]propanamide",NULL,Classification|Patents,2,NULL,20191231,AbaChemScene|ChEMBL|MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,NULL
GRYRXFYWVDWPQY-UHFFFAOYSA-N,156,Q8IXJ6,SIRT2,CRBN,CC1=CC(C)=NC(SCC(=O)NC2=NC=C(CC3=CC=CC(OCC4=CN(CCCCNC(=O)COC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)N=N4)=C3)S2)=N1,NA,NA,NA,NA,NA,10.1021/acs.jmedchem.6b01872,852.956,852.2472002,3.49,-5.39,60,7,16,3,18,229.59,C40H40N10O8S2,"InChI=1S/C40H40N10O8S2/c1-23-15-24(2)44-40(43-23)59-22-34(53)46-39-42-18-28(60-39)17-25-7-5-8-27(16-25)57-20-26-19-49(48-47-26)14-4-3-13-41-33(52)21-58-31-10-6-9-29-35(31)38(56)50(37(29)55)30-11-12-32(51)45-36(30)54/h5-10,15-16,18-19,30H,3-4,11-14,17,20-22H2,1-2H3,(H,41,52)(H,42,46,53)(H,45,51,54)",135397670,PROTAC Sirt2 Degrader-1,"Sirt2-PROTAC-1|PROTAC Sirt2 Degrader-1|2098487-75-1|CHEMBL4225467|2-((4,6-Dimethylpyrimidin-2-yl)thio)-N-(5-(3-((1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methoxy)benzyl)thiazol-2-yl)acetamide|BDBM50459841|AKOS037653400|HY-103636|CS-0028486",852.9,C40H40N10O8S2,283,1540,3.2,60,3,15,18,"InChI=1S/C40H40N10O8S2/c1-23-15-24(2)44-40(43-23)59-22-34(53)46-39-42-18-28(60-39)17-25-7-5-8-27(16-25)57-20-26-19-49(48-47-26)14-4-3-13-41-33(52)21-58-31-10-6-9-29-35(31)38(56)50(37(29)55)30-11-12-32(51)45-36(30)54/h5-10,15-16,18-19,30H,3-4,11-14,17,20-22H2,1-2H3,(H,41,52)(H,42,46,53)(H,45,51,54)",CC1=CC(=NC(=N1)SCC(=O)NC2=NC=C(S2)CC3=CC(=CC=C3)OCC4=CN(N=N4)CCCCNC(=O)COC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O)C,"N-[4-[4-[[3-[[2-[[2-(4,6-dimethylpyrimidin-2-yl)sulfanylacetyl]amino]-1,3-thiazol-5-yl]methyl]phenoxy]methyl]triazol-1-yl]butyl]-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetamide",NULL,Biological Test Results|Classification|Biological Test Results: Active|Biological Test Results: Micromolar,4,1387857|1387858|1387859|1387860|1387861|1387862|1387864|1387865|1387866|1387867,20181227,A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|Chem-Space.com Database|ChEMBL|CSNpharm|DC Chemicals|eNovation Chemicals|MedChemexpress MCE|MolPort|Smolecule|THE BioTek,Chemical Vendors|Curation Efforts|Research and Development,NULL
HHMCHRRZMCHLLA-PYINPHMPSA-N,1285,Q07817,BCL-xL,XIAP,CN[C@@H](C)C(=O)N[C@H]1CCO[C@H]2CC(C)(C)[C@@H](C(=O)N[C@@H]3CCCC4=CC(OCCCC(=O)N5CCN(CC[C@H](CSC6=CC=CC=C6)NC6=CC=C(S(=O)(=O)NC(=O)C7=CC=C(N8CCN(CC9=C(C%10=CC=C(Cl)C=C%10)CCC(C)(C)C9)CC8)C=C7)C=C6S(=O)(=O)C(F)(F)F)CC5)=CC=C43)N2C1=O,NA,NA,NA,NA,NA,10.1016/j.ejmech.2020.112397,1514.311,1512.606279,7.29,-5.74,104,11,17,5,26,248.44,C76H96ClF3N10O11S3,"InChI=1S/C76H96ClF3N10O11S3/c1-50(81-6)70(92)84-65-31-43-101-68-47-75(4,5)69(90(68)73(65)95)72(94)83-63-15-10-12-53-44-58(25-27-62(53)63)100-42-11-16-67(91)89-40-34-86(35-41-89)33-30-56(49-102-59-13-8-7-9-14-59)82-64-28-26-60(45-66(64)103(96,97)76(78,79)80)104(98,99)85-71(93)52-19-23-57(24-20-52)88-38-36-87(37-39-88)48-54-46-74(2,3)32-29-61(54)51-17-21-55(77)22-18-51/h7-9,13-14,17-28,44-45,50,56,63,65,68-69,81-82H,10-12,15-16,29-43,46-49H2,1-6H3,(H,83,94)(H,84,92)(H,85,93)/t50-,56+,63+,65-,68-,69+/m0/s1",146673056,PROTAC Bcl-xL degrader-1,PROTAC Bcl-xL degrader-1|HY-131188|CS-0130227,1514.3,C76H96ClF3N10O11S3,291,3160,11.5,104,5,20,26,"InChI=1S/C76H96ClF3N10O11S3/c1-50(81-6)70(92)84-65-31-43-101-68-47-75(4,5)69(90(68)73(65)95)72(94)83-63-15-10-12-53-44-58(25-27-62(53)63)100-42-11-16-67(91)89-40-34-86(35-41-89)33-30-56(49-102-59-13-8-7-9-14-59)82-64-28-26-60(45-66(64)103(96,97)76(78,79)80)104(98,99)85-71(93)52-19-23-57(24-20-52)88-38-36-87(37-39-88)48-54-46-74(2,3)32-29-61(54)51-17-21-55(77)22-18-51/h7-9,13-14,17-28,44-45,50,56,63,65,68-69,81-82H,10-12,15-16,29-43,46-49H2,1-6H3,(H,83,94)(H,84,92)(H,85,93)/t50-,56+,63+,65-,68-,69+/m0/s1",C[C@@H](C(=O)N[C@H]1CCO[C@H]2CC([C@H](N2C1=O)C(=O)N[C@@H]3CCCC4=C3C=CC(=C4)OCCCC(=O)N5CCN(CC5)CC[C@H](CSC6=CC=CC=C6)NC7=C(C=C(C=C7)S(=O)(=O)NC(=O)C8=CC=C(C=C8)N9CCN(CC9)CC1=C(CCC(C1)(C)C)C1=CC=C(C=C1)Cl)S(=O)(=O)C(F)(F)F)(C)C)NC,"(4S,7S,9aS)-N-[(1R)-6-[4-[4-[(3R)-3-[4-[[4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperazin-1-yl]-4-oxobutoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-8,8-dimethyl-4-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-2,3,4,7,9,9a-hexahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide",NULL,NULL,0,NULL,20200702,AbaChemScene|MedChemexpress MCE,Chemical Vendors,NULL
IKJBYQODYFQASC-YKCITUTQSA-N,274,P36888,FLT-3,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOC3=CC=C4C(=C3)SC3=NC(C5=CC=C(NC(=O)NC6=NOC(C(C)(C)C)=C6)C=C5)=CN34)C(C)(C)C)C=C2)SC=N1,NA,NA,NA,NA,NA,10.1021/jacs.8b10320,1020.248,1019.403367,5.95,-4.76,72,8,15,5,19,223.78,C52H61N9O9S2,"InChI=1S/C52H61N9O9S2/c1-31-45(71-30-54-31)34-10-8-32(9-11-34)27-53-47(64)40-24-36(62)28-60(40)48(65)46(52(5,6)7)58-44(63)18-19-67-20-21-68-22-23-69-37-16-17-39-41(25-37)72-50-56-38(29-61(39)50)33-12-14-35(15-13-33)55-49(66)57-43-26-42(70-59-43)51(2,3)4/h8-17,25-26,29-30,36,40,46,62H,18-24,27-28H2,1-7H3,(H,53,64)(H,58,63)(H2,55,57,59,66)/t36-,40+,46-/m1/s1",135172387,PROTAC FLT-3 degrader 1,PROTAC FLT-3 degrader 1|CHEMBL4555872|SCHEMBL20322436|AKOS037653383|HY-114323|CS-0082105,1020.2,C52H61N9O9S2,280,1800,7.7,72,5,14,21,"InChI=1S/C52H61N9O9S2/c1-31-45(71-30-54-31)34-10-8-32(9-11-34)27-53-47(64)40-24-36(62)28-60(40)48(65)46(52(5,6)7)58-44(63)18-19-67-20-21-68-22-23-69-37-16-17-39-41(25-37)72-50-56-38(29-61(39)50)33-12-14-35(15-13-33)55-49(66)57-43-26-42(70-59-43)51(2,3)4/h8-17,25-26,29-30,36,40,46,62H,18-24,27-28H2,1-7H3,(H,53,64)(H,58,63)(H2,55,57,59,66)/t36-,40+,46-/m1/s1",CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCOCCOCCOC4=CC5=C(C=C4)N6C=C(N=C6S5)C7=CC=C(C=C7)NC(=O)NC8=NOC(=C8)C(C)(C)C)O,"(2S,4R)-1-[(2S)-2-[3-[2-[2-[2-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]imidazo[2,1-b][1,3]benzothiazol-6-yl]oxyethoxy]ethoxy]propanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,Classification|Patents,2,NULL,20181215,AbaChemScene|AKos Consulting & Solutions|BenchChem|ChEMBL|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,NULL
LJDTZKKSXVIAPQ-FATAJGLMSA-N,695,P29373,CRABP-II,cIAP1,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CC/C1=N\OCC(=O)NCCOCCOCCOC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1,NA,NA,NA,NA,NA,10.1021/ja100691p,809.014,808.4622442,2,-5.95,58,2,11,5,25,208.1,C44H64N4O10,"InChI=1S/C44H64N4O10/c1-30(2)26-38(47-42(53)41(52)36(45)28-34-14-9-8-10-15-34)43(54)57-25-24-56-23-22-55-21-20-46-39(49)29-58-48-37-18-19-44(6,7)35(33(37)5)17-16-31(3)12-11-13-32(4)27-40(50)51/h8-17,27,30,36,38,41,52H,18-26,28-29,45H2,1-7H3,(H,46,49)(H,47,53)(H,50,51)/b13-11+,17-16+,31-12+,32-27+,48-37+/t36-,38+,41+/m1/s1",46218170,PROTAC CRABP-II Degrader-2,PROTAC CRABP-II Degrader-2|CHEMBL2048499|AKOS037653380|HY-111841|CS-0093180,809,C44H64N4O10,208,1520,3.6,58,5,12,26,"InChI=1S/C44H64N4O10/c1-30(2)26-38(47-42(53)41(52)36(45)28-34-14-9-8-10-15-34)43(54)57-25-24-56-23-22-55-21-20-46-39(49)29-58-48-37-18-19-44(6,7)35(33(37)5)17-16-31(3)12-11-13-32(4)27-40(50)51/h8-17,27,30,36,38,41,52H,18-26,28-29,45H2,1-7H3,(H,46,49)(H,47,53)(H,50,51)/b13-11+,17-16+,31-12+,32-27+,48-37+/t36-,38+,41+/m1/s1",CC\\1=C(C(CC/C1=N\\OCC(=O)NCCOCCOCCOC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](CC2=CC=CC=C2)N)O)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,"(2E,4E,6E,8E)-9-[(3E)-3-[2-[2-[2-[2-[(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoyl]oxyethoxy]ethoxy]ethylamino]-2-oxoethoxy]imino-2,6,6-trimethylcyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenoic acid",NULL,Biological Test Results|Classification,2,670302|670307|670308|670309|690787|690797|704677|704693|704694|704695|704696,20100706,AbaChemScene|AKos Consulting & Solutions|ChEMBL|DiscoveryGate|MedChemexpress MCE|Thomson Pharma,Chemical Vendors|Curation Efforts|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,NULL
LJDTZKKSXVIAPQ-FATAJGLMSA-N,695,P29762,CRABP-I,cIAP1,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CC/C1=N\OCC(=O)NCCOCCOCCOC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1,NA,NA,NA,NA,NA,10.1021/ja100691p,809.014,808.4622442,2,-5.95,58,2,11,5,25,208.1,C44H64N4O10,"InChI=1S/C44H64N4O10/c1-30(2)26-38(47-42(53)41(52)36(45)28-34-14-9-8-10-15-34)43(54)57-25-24-56-23-22-55-21-20-46-39(49)29-58-48-37-18-19-44(6,7)35(33(37)5)17-16-31(3)12-11-13-32(4)27-40(50)51/h8-17,27,30,36,38,41,52H,18-26,28-29,45H2,1-7H3,(H,46,49)(H,47,53)(H,50,51)/b13-11+,17-16+,31-12+,32-27+,48-37+/t36-,38+,41+/m1/s1",46218170,PROTAC CRABP-II Degrader-2,PROTAC CRABP-II Degrader-2|CHEMBL2048499|AKOS037653380|HY-111841|CS-0093180,809,C44H64N4O10,208,1520,3.6,58,5,12,26,"InChI=1S/C44H64N4O10/c1-30(2)26-38(47-42(53)41(52)36(45)28-34-14-9-8-10-15-34)43(54)57-25-24-56-23-22-55-21-20-46-39(49)29-58-48-37-18-19-44(6,7)35(33(37)5)17-16-31(3)12-11-13-32(4)27-40(50)51/h8-17,27,30,36,38,41,52H,18-26,28-29,45H2,1-7H3,(H,46,49)(H,47,53)(H,50,51)/b13-11+,17-16+,31-12+,32-27+,48-37+/t36-,38+,41+/m1/s1",CC\\1=C(C(CC/C1=N\\OCC(=O)NCCOCCOCCOC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](CC2=CC=CC=C2)N)O)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,"(2E,4E,6E,8E)-9-[(3E)-3-[2-[2-[2-[2-[(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoyl]oxyethoxy]ethoxy]ethylamino]-2-oxoethoxy]imino-2,6,6-trimethylcyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenoic acid",NULL,Biological Test Results|Classification,2,670302|670307|670308|670309|690787|690797|704677|704693|704694|704695|704696,20100706,AbaChemScene|AKos Consulting & Solutions|ChEMBL|DiscoveryGate|MedChemexpress MCE|Thomson Pharma,Chemical Vendors|Curation Efforts|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,NULL
LOLHUPGCPDURJG-UHFFFAOYSA-N,1187,Q9H8M2,BRD9,CRBN,COC1=CC(C2=CN(C)C(=O)C3=C2SC(C(=N)NC2CCS(=O)(=O)CC2)=C3)=CC=C1OCC(=O)NCCCCNC(=O)COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,NA,NA,NA,NA,NA,10.1002/anie.201611281,903.993,903.2567619,2.09,-5.2,63,7,15,5,16,261.46,C42H45N7O12S2,"InChI=1S/C42H45N7O12S2/c1-48-20-27(37-26(40(48)54)19-32(62-37)38(43)46-24-12-16-63(57,58)17-13-24)23-8-10-29(31(18-23)59-2)60-21-34(51)44-14-3-4-15-45-35(52)22-61-30-7-5-6-25-36(30)42(56)49(41(25)55)28-9-11-33(50)47-39(28)53/h5-8,10,18-20,24,28H,3-4,9,11-17,21-22H2,1-2H3,(H2,43,46)(H,44,51)(H,45,52)(H,47,50,53)",137628637,PROTAC BRD9 Degrader-1,"PROTAC BRD9 Degrader-1|2097971-01-0|SCHEMBL21259422|BCP30517|EX-A3889|AKOS037653394|HY-103632|CS-0028482|(Z)-2-(4-(2-(N'-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbamimidoyl)-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridin-7-yl)-2-methoxyphenoxy)-N-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)acetamide",904,C42H45N7O12S2,299,1960,0.8,63,4,14,16,"InChI=1S/C42H45N7O12S2/c1-48-20-27(37-26(40(48)54)19-32(62-37)38(43)46-24-12-16-63(57,58)17-13-24)23-8-10-29(31(18-23)59-2)60-21-34(51)44-14-3-4-15-45-35(52)22-61-30-7-5-6-25-36(30)42(56)49(41(25)55)28-9-11-33(50)47-39(28)53/h5-8,10,18-20,24,28H,3-4,9,11-17,21-22H2,1-2H3,(H2,43,46)(H,44,51)(H,45,52)(H,47,50,53)",CN1C=C(C2=C(C1=O)C=C(S2)C(=NC3CCS(=O)(=O)CC3)N)C4=CC(=C(C=C4)OCC(=O)NCCCCNC(=O)COC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O)OC,"N-[4-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]butyl]-2-[4-[2-[N'-(1,1-dioxothian-4-yl)carbamimidoyl]-5-methyl-4-oxothieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy]acetamide",NULL,Patents,1,NULL,20190408,A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|BenchChem|BioChemPartner|BOC Sciences|Chem-Space.com Database|ChemShuttle|CSNpharm|Excenen Pharmatech|MedChemexpress MCE|MolPort|SureChEMBL|TargetMol (Target Molecule Corp.),Chemical Vendors|Curation Efforts|Legacy Depositors|Research and Development,NULL
MMDOSMHAAYKBET-UTCZBAMKSA-N,732,P03372,ER,cIAP1,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(=O)NCCOCCOCCNC(=O)CO/N=C1\CC[C@H]2[C@@H]3CCC4=CC(O)=CC=C4[C@H]3CC[C@]12C,NA,NA,NA,NA,NA,10.1016/j.bmc.2011.09.041,763.977,763.4520139,3.6,-5.58,55,5,10,6,20,193.83,C42H61N5O8,"InChI=1S/C42H61N5O8/c1-27(2)23-36(46-41(52)39(50)35(43)24-28-7-5-4-6-8-28)40(51)45-18-20-54-22-21-53-19-17-44-38(49)26-55-47-37-14-13-34-33-11-9-29-25-30(48)10-12-31(29)32(33)15-16-42(34,37)3/h4-8,10,12,25,27,32-36,39,48,50H,9,11,13-24,26,43H2,1-3H3,(H,44,49)(H,45,51)(H,46,52)/b47-37+/t32-,33-,34+,35-,36+,39+,42+/m1/s1",54764406,PROTAC ERalpha Degrader-2,PROTAC ERalpha Degrader-2|CHEMBL2151739|AKOS037653374|HY-111846|CS-0093244,764,C42H61N5O8,194,1260,4.1,55,6,10,20,"InChI=1S/C42H61N5O8/c1-27(2)23-36(46-41(52)39(50)35(43)24-28-7-5-4-6-8-28)40(51)45-18-20-54-22-21-53-19-17-44-38(49)26-55-47-37-14-13-34-33-11-9-29-25-30(48)10-12-31(29)32(33)15-16-42(34,37)3/h4-8,10,12,25,27,32-36,39,48,50H,9,11,13-24,26,43H2,1-3H3,(H,44,49)(H,45,51)(H,46,52)/b47-37+/t32-,33-,34+,35-,36+,39+,42+/m1/s1",CC(C)C[C@@H](C(=O)NCCOCCOCCNC(=O)CO/N=C/1\\CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C)NC(=O)[C@H]([C@@H](CC5=CC=CC=C5)N)O,"(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-N-[2-[2-[2-[[2-[(E)-[(8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ylidene]amino]oxyacetyl]amino]ethoxy]ethoxy]ethyl]-4-methylpentanamide",NULL,Biological Test Results|Classification,2,690790,20120116,AbaChemScene|AKos Consulting & Solutions|BenchChem|ChEMBL|MedChemexpress MCE|MolPort|Thomson Pharma,Chemical Vendors|Curation Efforts|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,NULL
MVULIYLBRNHLEE-LFHXYJAASA-N,267,Q05397,FAK,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,3,99,Degradation of Fak in PC3 cells after 24 h treatment,NA,NA,10.1021/jacs.8b08008,996.148,995.3645364,5.46,-5.8,69,6,14,5,20,217.31,C47H56F3N9O8S2,"InChI=1S/C47H56F3N9O8S2/c1-29-40(68-28-54-29)32-12-10-30(11-13-32)24-52-43(62)38-23-35(60)27-59(38)44(63)41(46(2,3)4)56-39(61)18-19-66-20-21-67-36-16-14-33(15-17-36)55-45-53-26-37(47(48,49)50)42(57-45)51-25-31-8-7-9-34(22-31)58(5)69(6,64)65/h7-17,22,26,28,35,38,41,60H,18-21,23-25,27H2,1-6H3,(H,52,62)(H,56,61)(H2,51,53,55,57)/t35-,38+,41-/m1/s1",138454773,PROTAC FAK degrader 1,PROTAC FAK degrader 1|CHEMBL4447794|SCHEMBL21634231|2301916-69-6|EX-A3967|BDBM50520571|HY-119932|CS-0078799,996.1,C47H56F3N9O8S2,254,1760,5.8,69,5,18,21,"InChI=1S/C47H56F3N9O8S2/c1-29-40(68-28-54-29)32-12-10-30(11-13-32)24-52-43(62)38-23-35(60)27-59(38)44(63)41(46(2,3)4)56-39(61)18-19-66-20-21-67-36-16-14-33(15-17-36)55-45-53-26-37(47(48,49)50)42(57-45)51-25-31-8-7-9-34(22-31)58(5)69(6,64)65/h7-17,22,26,28,35,38,41,60H,18-21,23-25,27H2,1-6H3,(H,52,62)(H,56,61)(H2,51,53,55,57)/t35-,38+,41-/m1/s1",CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCOCCOC4=CC=C(C=C4)NC5=NC=C(C(=N5)NCC6=CC(=CC=C6)N(C)S(=O)(=O)C)C(F)(F)F)O,"(2S,4R)-1-[(2S)-3,3-dimethyl-2-[3-[2-[4-[[4-[[3-[methyl(methylsulfonyl)amino]phenyl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]phenoxy]ethoxy]propanoylamino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,Classification|Patents,2,NULL,20190712,AbaChemScene|BenchChem|BindingDB|Chem-Space.com Database|ChEMBL|Excenen Pharmatech|Google Patents|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol (Target Molecule Corp.),Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development,NULL
NICKHWYZMNLEPJ-TZSMONEZSA-N,276,P00533,EGFR,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,11.7/22.3,98.9/96.6,Degradation of Exon 19 del/L858R EGFR in HCC827/H3255 cells after 24 h treatment,NA,NA,10.1016/j.chembiol.2017.09.009,934.532,933.3661887,5.84,-6.31,65,6,13,4,22,186.36,C47H57ClFN7O8S,"InChI=1S/C47H57ClFN7O8S/c1-29-42(65-28-53-29)31-11-9-30(10-12-31)25-50-45(59)38-22-33(57)26-56(38)46(60)43(47(2,3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14,21,23-24,27-28,33,38,43,57H,6-8,15-20,22,25-26H2,1-5H3,(H,50,59)(H,55,58)(H,51,52,54)/t33-,38+,43-/m1/s1",135156947,Gefitinib-based PROTAC 3,"Gefitinib-based PROTAC 3|2230821-27-7|PROTAC 3|CHEMBL4587573|SCHEMBL20305518|GTPL10636|EX-A3010|NTN21277|AKOS037653377|HY-123921|CS-0087480|S0070|(2S,4R)-1-((S)-2-(3-(2-((5-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)oxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide",934.5,C47H57ClFN7O8S,215,1480,6.9,65,4,14,23,"InChI=1S/C47H57ClFN7O8S/c1-29-42(65-28-53-29)31-11-9-30(10-12-31)25-50-45(59)38-22-33(57)26-56(38)46(60)43(47(2,3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14,21,23-24,27-28,33,38,43,57H,6-8,15-20,22,25-26H2,1-5H3,(H,50,59)(H,55,58)(H,51,52,54)/t33-,38+,43-/m1/s1",CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCOCCOCCCCCOC4=C(C=C5C(=C4)C(=NC=N5)NC6=CC(=C(C=C6)F)Cl)OC)O,"(2S,4R)-1-[(2S)-2-[3-[2-[5-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypentoxy]ethoxy]propanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,Classification|Literature|Patents,3,NULL,20181215,A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|Chem-Space.com Database|ChEMBL|eNovation Chemicals|Excenen Pharmatech|IUPHAR/BPS Guide to PHARMACOLOGY|Lan Pharmatech|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Selleck Chemicals|SureChEMBL|TargetMol (Target Molecule Corp.)|THE BioTek,Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development,NULL
OXIPFLHBDVDLDS-UHFFFAOYSA-N,296,Q96SW2,CRBN,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)=C3C2=O)C(=O)N1,NA,NA,NA,NA,NA,10.1021/acschembio.8b00693,660.64,660.2179912,1.95,-3.41,48,6,12,4,13,209.62,C32H32N6O10,"InChI=1S/C32H32N6O10/c39-23-9-7-21(27(41)35-23)37-29(43)17-3-1-5-19(25(17)31(37)45)33-11-13-47-15-16-48-14-12-34-20-6-2-4-18-26(20)32(46)38(30(18)44)22-8-10-24(40)36-28(22)42/h1-6,21-22,33-34H,7-16H2,(H,35,39,41)(H,36,40,42)",137628659,Homo-PROTAC cereblon degrader 1,"Homo-PROTAC cereblon degrader 1|2244520-98-5|4,4'-(((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(azanediyl))bis(2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione)|CHEMBL4435661|EX-A3970|OUN20985|s2881|AKOS037653338|HY-111594|CS-0087832",660.6,C32H32N6O10,210,1260,0.8,48,4,12,13,"InChI=1S/C32H32N6O10/c39-23-9-7-21(27(41)35-23)37-29(43)17-3-1-5-19(25(17)31(37)45)33-11-13-47-15-16-48-14-12-34-20-6-2-4-18-26(20)32(46)38(30(18)44)22-8-10-24(40)36-28(22)42/h1-6,21-22,33-34H,7-16H2,(H,35,39,41)(H,36,40,42)",C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCOCCOCCNC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O,"2-(2,6-dioxopiperidin-3-yl)-4-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethylamino]isoindole-1,3-dione",NULL,Classification,1,NULL,20190408,A2B Chem|AA BLOCKS|AbaChemScene|AbMole Bioscience|AKos Consulting & Solutions|Ambeed|Axon Medchem|BenchChem|BLD Pharm|BOC Sciences|Chem-Space.com Database|ChEMBL|ChemShuttle|CSNpharm|Excenen Pharmatech|Lan Pharmatech|MedChemexpress MCE|MolPort|Selleck Chemicals|TargetMol (Target Molecule Corp.),Chemical Vendors|Curation Efforts|Legacy Depositors|Research and Development,NULL
PEZCAXDTKNFUCR-CTMFSBKBSA-N,968,Q96SW2,CRBN,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCOCCOCCCCCOCC(=O)NCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,200/230,75/98,Degradation of CRBN in HeLa/HEK293 cells,NA,NA,10.1016/j.bmc.2019.02.048,1061.269,1060.493955,3.96,-5.82,75,6,16,6,30,273.23,C53H72N8O13S,"InChI=1S/C53H72N8O13S/c1-34-46(75-33-57-34)36-16-14-35(15-17-36)29-56-48(66)41-28-37(62)30-60(41)52(70)47(53(2,3)4)58-44(65)32-74-25-10-6-8-23-72-27-26-71-22-7-5-9-24-73-31-43(64)55-21-20-54-39-13-11-12-38-45(39)51(69)61(50(38)68)40-18-19-42(63)59-49(40)67/h11-17,33,37,40-41,47,54,62H,5-10,18-32H2,1-4H3,(H,55,64)(H,56,66)(H,58,65)(H,59,63,67)/t37-,40?,41+,47-/m1/s1",138911387,PROTAC CRBN Degrader-1,PROTAC CRBN Degrader-1|HY-128845|CS-0100674,1061.3,C53H72N8O13S,302,1920,3.7,75,6,16,31,"InChI=1S/C53H72N8O13S/c1-34-46(75-33-57-34)36-16-14-35(15-17-36)29-56-48(66)41-28-37(62)30-60(41)52(70)47(53(2,3)4)58-44(65)32-74-25-10-6-8-23-72-27-26-71-22-7-5-9-24-73-31-43(64)55-21-20-54-39-13-11-12-38-45(39)51(69)61(50(38)68)40-18-19-42(63)59-49(40)67/h11-17,33,37,40-41,47,54,62H,5-10,18-32H2,1-4H3,(H,55,64)(H,56,66)(H,58,65)(H,59,63,67)/t37-,40?,41+,47-/m1/s1",CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)COCCCCCOCCOCCCCCOCC(=O)NCCNC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O)O,"(2S,4R)-1-[(2S)-2-[[2-[5-[2-[5-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethylamino]-2-oxoethoxy]pentoxy]ethoxy]pentoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,NULL,NA,NULL,20190902,AbaChemScene|BenchChem|Chem-Space.com Database|MedChemexpress MCE|MolPort,Chemical Vendors,NULL
QCULBRPVCWJUKY-OUMVKTTMSA-N,796,Q86U86,PBRM1,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,NA,NA,NA,NA,NA,10.1038/s41589-019-0294-6,918.106,917.4269591,3.63,-5.52,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",137628626,"(2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-Azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide","(2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide|PROTAC 1|SCHEMBL21902924|FX8",918.1,C46H60FN9O8S,246,1560,3.2,65,5,16,20,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",CC1=C(SC=N1)C2=CC(=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)C4(CC4)F)O)OCCOCCOCCN5CCN(CC5)C6=CC(=NN=C6N)C7=CC=CC=C7O,"(2S,4R)-N-[[2-[2-[2-[2-[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2S)-2-[(1-fluorocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide",NULL,Biomolecular Interactions and Pathways|Literature|Patents,3,NULL,20190408,Nature Chemical Biology|NCBI Structure|PATENTSCOPE (WIPO)|Protein Data Bank in Europe (PDBe)|SureChEMBL,Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development,NULL
QCULBRPVCWJUKY-OUMVKTTMSA-N,796,P51532,SMARCA4,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,250,70,Degradation of SMARCA4 in MV-4-11 cells  after 18 h treatment,NA,NA,10.1038/s41589-019-0294-6,918.106,917.4269591,3.63,-5.52,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",137628626,"(2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-Azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide","(2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide|PROTAC 1|SCHEMBL21902924|FX8",918.1,C46H60FN9O8S,246,1560,3.2,65,5,16,20,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",CC1=C(SC=N1)C2=CC(=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)C4(CC4)F)O)OCCOCCOCCN5CCN(CC5)C6=CC(=NN=C6N)C7=CC=CC=C7O,"(2S,4R)-N-[[2-[2-[2-[2-[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2S)-2-[(1-fluorocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide",NULL,Biomolecular Interactions and Pathways|Literature|Patents,3,NULL,20190408,Nature Chemical Biology|NCBI Structure|PATENTSCOPE (WIPO)|Protein Data Bank in Europe (PDBe)|SureChEMBL,Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development,NULL
QCULBRPVCWJUKY-OUMVKTTMSA-N,796,P51531,SMARCA2,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,300,65,Degradation of SMARCA2 in MV-4-11 cells after 18 h treatment,NA,NA,10.1038/s41589-019-0294-6,918.106,917.4269591,3.63,-5.52,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",137628626,"(2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-Azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide","(2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide|PROTAC 1|SCHEMBL21902924|FX8",918.1,C46H60FN9O8S,246,1560,3.2,65,5,16,20,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",CC1=C(SC=N1)C2=CC(=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)C4(CC4)F)O)OCCOCCOCCN5CCN(CC5)C6=CC(=NN=C6N)C7=CC=CC=C7O,"(2S,4R)-N-[[2-[2-[2-[2-[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2S)-2-[(1-fluorocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide",NULL,Biomolecular Interactions and Pathways|Literature|Patents,3,NULL,20190408,Nature Chemical Biology|NCBI Structure|PATENTSCOPE (WIPO)|Protein Data Bank in Europe (PDBe)|SureChEMBL,Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development,NULL
RIEGJNXDHULIKM-GPPJZCFZSA-N,334,O43353,RIPK2,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOC3=CC4=NC=CC(NC5=CC=C6SC=NC6=C5)=C4C=C3S(=O)(=O)C(C)(C)C)C(C)(C)C)C=C2)SC=N1,2,NA,Degradation of RIPK2 in THP-1 cells after 18 h treatment,NA,NA,10.1038/s42003-020-0868-6,1060.331,1059.390419,5.13,-5.93,73,7,17,4,24,229.73,C52H65N7O11S3,"InChI=1S/C52H65N7O11S3/c1-33-47(72-31-55-33)35-10-8-34(9-11-35)28-54-49(62)42-25-37(60)29-59(42)50(63)48(51(2,3)4)58-46(61)30-69-21-20-67-17-16-66-18-19-68-22-23-70-43-27-40-38(26-45(43)73(64,65)52(5,6)7)39(14-15-53-40)57-36-12-13-44-41(24-36)56-32-71-44/h8-15,24,26-27,31-32,37,42,48,60H,16-23,25,28-30H2,1-7H3,(H,53,57)(H,54,62)(H,58,61)/t37-,42+,48-/m1/s1",91799297,PROTAC RIPK degrader-2,"PROTAC_RIPK2|PROTAC RIPK degrader-2|CHEMBL4098772|1801547-16-9|RGN47169|BDBM50246759|HY-111866|CS-0093284|(2S,4R)-1-((S)-17-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide|(2S,4R)-1-((S)-17-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol",1060.3,C52H65N7O11S3,295,1870,5.9,73,4,17,26,"InChI=1S/C52H65N7O11S3/c1-33-47(72-31-55-33)35-10-8-34(9-11-35)28-54-49(62)42-25-37(60)29-59(42)50(63)48(51(2,3)4)58-46(61)30-69-21-20-67-17-16-66-18-19-68-22-23-70-43-27-40-38(26-45(43)73(64,65)52(5,6)7)39(14-15-53-40)57-36-12-13-44-41(24-36)56-32-71-44/h8-15,24,26-27,31-32,37,42,48,60H,16-23,25,28-30H2,1-7H3,(H,53,57)(H,54,62)(H,58,61)/t37-,42+,48-/m1/s1",CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)COCCOCCOCCOCCOC4=CC5=NC=CC(=C5C=C4S(=O)(=O)C(C)(C)C)NC6=CC7=C(C=C6)SC=N7)O,"(2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,Biological Test Results|Classification|Literature|Biological Test Results: Active|Biological Test Results: Micromolar,5,1471891|1471892,20150608,AbaChemScene|BindingDB|BLD Pharm|ChEMBL|Japan Chemical Substance Dictionary (Nikkaji)|MedChemexpress MCE|MolPort|Nature Chemical Biology|Springer Nature|THE BioTek,Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development,NULL
RTFQFPZKDYMMMJ-RIAKQDHQSA-N,929,Q96BR1,SGK3,VHL,CC1=CC=C(F)C(S(=O)(=O)NC2=CC=C(C3=NC(OC[C@H]4CN(CCCCCCOCCOCCOCC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)NCC5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CCO4)=C4C=N[NH]C4=N3)C=C2)=C1,NA,NA,NA,NA,NA,10.1021/acschembio.9b00505,1157.402,1156.488573,5.23,-6.16,81,8,17,5,28,261.65,C57H73FN10O11S2,"InChI=1S/C57H73FN10O11S2/c1-37-10-19-46(58)48(28-37)81(73,74)66-42-17-15-41(16-18-42)52-63-53-45(31-61-65-53)55(64-52)79-34-44-33-67(21-23-78-44)20-8-6-7-9-22-75-24-25-76-26-27-77-35-49(70)62-51(57(3,4)5)56(72)68-32-43(69)29-47(68)54(71)59-30-39-11-13-40(14-12-39)50-38(2)60-36-80-50/h10-19,28,31,36,43-44,47,51,66,69H,6-9,20-27,29-30,32-35H2,1-5H3,(H,59,71)(H,62,70)(H,61,63,64,65)/t43-,44-,47+,51-/m1/s1",139035049,PROTAC SGK3 degrader-1,"PROTAC SGK3 degrader-1|SGK3 degrader-1|EX-A3963|HY-125878|CS-0102619|(2S,4R)-1-((S)-2-(tert-butyl)-18-((R)-2-(((6-(4-(2-fluoro-5-methylphenylsulfonamido)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)methyl)morpholino)-4-oxo-6,9,12-trioxa-3-azaoctadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide|2381320-35-8",1157.4,C57H73FN10O11S2,298,2050,6,81,5,19,29,"InChI=1S/C57H73FN10O11S2/c1-37-10-19-46(58)48(28-37)81(73,74)66-42-17-15-41(16-18-42)52-63-53-45(31-61-65-53)55(64-52)79-34-44-33-67(21-23-78-44)20-8-6-7-9-22-75-24-25-76-26-27-77-35-49(70)62-51(57(3,4)5)56(72)68-32-43(69)29-47(68)54(71)59-30-39-11-13-40(14-12-39)50-38(2)60-36-80-50/h10-19,28,31,36,43-44,47,51,66,69H,6-9,20-27,29-30,32-35H2,1-5H3,(H,59,71)(H,62,70)(H,61,63,64,65)/t43-,44-,47+,51-/m1/s1",CC1=CC(=C(C=C1)F)S(=O)(=O)NC2=CC=C(C=C2)C3=NC4=C(C=NN4)C(=N3)OC[C@H]5CN(CCO5)CCCCCCOCCOCCOCC(=O)N[C@H](C(=O)N6C[C@@H](C[C@H]6C(=O)NCC7=CC=C(C=C7)C8=C(N=CS8)C)O)C(C)(C)C,"(2S,4R)-1-[(2S)-2-[[2-[2-[2-[6-[(2R)-2-[[6-[4-[(2-fluoro-5-methylphenyl)sulfonylamino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxymethyl]morpholin-4-yl]hexoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,NULL,NA,NULL,20190930,AbaChemScene|AbMole Bioscience|BenchChem|Chem-Space.com Database|ChemShuttle|Excenen Pharmatech|MedChemexpress MCE|MolPort|TargetMol (Target Molecule Corp.),Chemical Vendors|Legacy Depositors,NULL
VKTBFTIPDGAIPC-BIOIQHPWSA-N,338,P10275,AR,MDM2,COC1=CC=C(C2=N[C@H](C3=CC=C(Cl)C=C3)[C@H](C3=CC=C(Cl)C=C3)N2C(=O)N2CCN(CC(=O)NCCOCCOCCOCC(=O)NC3=CC=C(OC[C@](C)(O)C(=O)NC4=CC=C([N+](=O)[O-])C(C(F)(F)F)=C4)C=C3)C(=O)C2)C(OC(C)C)=C1,NA,NA,NA,NA,NA,10.1016/j.bmcl.2008.07.114,1210.057,1208.363639,6.07,-6.32,84,7,15,4,26,262.27,C57H61Cl2F3N8O14,"InChI=1S/C57H61Cl2F3N8O14/c1-35(2)84-47-30-43(79-4)18-19-44(47)53-66-51(36-5-9-38(58)10-6-36)52(37-7-11-39(59)12-8-37)69(53)55(75)68-23-22-67(50(73)32-68)31-48(71)63-21-24-80-25-26-81-27-28-82-33-49(72)64-40-13-16-42(17-14-40)83-34-56(3,76)54(74)65-41-15-20-46(70(77)78)45(29-41)57(60,61)62/h5-20,29-30,35,51-52,76H,21-28,31-34H2,1-4H3,(H,63,71)(H,64,72)(H,65,74)/t51-,52+,56+/m1/s1",44582233,Sarm-Nutlin Protac,Sarm-Nutlin Protac|CHEMBL495553,1210,C57H61Cl2F3N8O14,265,2200,6.3,84,4,18,25,"InChI=1S/C57H61Cl2F3N8O14/c1-35(2)84-47-30-43(79-4)18-19-44(47)53-66-51(36-5-9-38(58)10-6-36)52(37-7-11-39(59)12-8-37)69(53)55(75)68-23-22-67(50(73)32-68)31-48(71)63-21-24-80-25-26-81-27-28-82-33-49(72)64-40-13-16-42(17-14-40)83-34-56(3,76)54(74)65-41-15-20-46(70(77)78)45(29-41)57(60,61)62/h5-20,29-30,35,51-52,76H,21-28,31-34H2,1-4H3,(H,63,71)(H,64,72)(H,65,74)/t51-,52+,56+/m1/s1",CC(C)OC1=C(C=CC(=C1)OC)C2=N[C@@H]([C@@H](N2C(=O)N3CCN(C(=O)C3)CC(=O)NCCOCCOCCOCC(=O)NC4=CC=C(C=C4)OC[C@@](C)(C(=O)NC5=CC(=C(C=C5)[N+](=O)[O-])C(F)(F)F)O)C6=CC=C(C=C6)Cl)C7=CC=C(C=C7)Cl,"(2S)-3-[4-[[2-[2-[2-[2-[[2-[4-[(4R,5S)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]-2-oxopiperazin-1-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]acetyl]amino]phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide",NULL,Biological Test Results|Literature,2,417067|417068,20100126,ChEMBL,Curation Efforts|Research and Development,NULL
WGJCHHJGGFCCRS-DEYDLUNASA-N,998,P40337,VHL,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)C(C)(C)C)C=C2)SC=N1,10-100,NA,Degradation of pVHL30 in HeLa cells after 24 h treatment,NA,NA,10.1038/s41467-017-00954-1,1179.47,1178.539191,3.54,-5.88,82,6,18,6,31,278.64,C58H82N8O14S2,"InChI=1S/C58H82N8O14S2/c1-37-49(81-35-61-37)41-13-9-39(10-14-41)29-59-53(71)45-27-43(67)31-65(45)55(73)51(57(3,4)5)63-47(69)33-79-25-23-77-21-19-75-17-18-76-20-22-78-24-26-80-34-48(70)64-52(58(6,7)8)56(74)66-32-44(68)28-46(66)54(72)60-30-40-11-15-42(16-12-40)50-38(2)62-36-82-50/h9-16,35-36,43-46,51-52,67-68H,17-34H2,1-8H3,(H,59,71)(H,60,72)(H,63,69)(H,64,70)/t43-,44-,45+,46+,51-,52-/m1/s1",134160242,Homo-PROTAC pVHL30 degrader 1,"Homo-PROTAC pVHL30 degrader 1|CM 11|2244684-49-7|N1,N20-bis((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-3,6,9,12,15,18-hexaoxaicosanediamide|CM11|SCHEMBL23431331|EX-A5064|AKOS034834077|HY-111593|CS-0087823",1179.5,C58H82N8O14S2,335,1870,3.6,82,6,18,33,"InChI=1S/C58H82N8O14S2/c1-37-49(81-35-61-37)41-13-9-39(10-14-41)29-59-53(71)45-27-43(67)31-65(45)55(73)51(57(3,4)5)63-47(69)33-79-25-23-77-21-19-75-17-18-76-20-22-78-24-26-80-34-48(70)64-52(58(6,7)8)56(74)66-32-44(68)28-46(66)54(72)60-30-40-11-15-42(16-12-40)50-38(2)62-36-82-50/h9-16,35-36,43-46,51-52,67-68H,17-34H2,1-8H3,(H,59,71)(H,60,72)(H,63,69)(H,64,70)/t43-,44-,45+,46+,51-,52-/m1/s1",CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)COCCOCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)NCC5=CC=C(C=C5)C6=C(N=CS6)C)O)C(C)(C)C)O,"(2S,4R)-4-hydroxy-1-[(2S)-2-[[2-[2-[2-[2-[2-[2-[2-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-2-oxoethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",NULL,Literature|Patents,2,NULL,20180620,AbaChemScene|AbMole Bioscience|AKos Consulting & Solutions|BenchChem|BLD Pharm|Chem-Space.com Database|ChemShuttle|Excenen Pharmatech|Google Patents|MedChemexpress MCE|MolPort|SureChEMBL|TargetMol (Target Molecule Corp.)|Tocris Bioscience,Chemical Vendors|Curation Efforts|Legacy Depositors|Research and Development,NULL
WNWBHGDKGOSOKU-QIINAUKOSA-N,1467,P03372,ER,VHL,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC(F)=C([C@@H]4C5=C(C[C@@H](C)N4CC(C)(C)F)C4=CC=CC=C4[NH]5)C(F)=C3)C(C)(C)C)C=C2)SC=N1,0.3,NA,Degradation of ERalpha in MCF7 cells,NA,NA,10.1021/acsmedchemlett.9b00397,1005.214,1004.469319,5.95,-6.18,71,7,11,4,21,167.58,C53H67F3N6O8S,"InChI=1S/C53H67F3N6O8S/c1-31-23-39-38-11-9-10-12-42(38)59-46(39)47(62(31)29-53(7,8)56)45-40(54)25-37(26-41(45)55)70-22-21-68-18-17-67-19-20-69-28-44(64)60-49(52(4,5)6)51(66)61-27-36(63)24-43(61)50(65)58-32(2)34-13-15-35(16-14-34)48-33(3)57-30-71-48/h9-16,25-26,30-32,36,43,47,49,59,63H,17-24,27-29H2,1-8H3,(H,58,65)(H,60,64)/t31-,32+,36-,43+,47-,49-/m1/s1",138693144,PROTAC ER Degrader-4,PROTAC ER Degrader-4|CHEMBL4476831|SCHEMBL21068257|BDBM50502988|HY-135309|CS-0111216|2361114-15-8,1005.2,C53H67F3N6O8S,196,1720,7.3,71,4,14,22,"InChI=1S/C53H67F3N6O8S/c1-31-23-39-38-11-9-10-12-42(38)59-46(39)47(62(31)29-53(7,8)56)45-40(54)25-37(26-41(45)55)70-22-21-68-18-17-67-19-20-69-28-44(64)60-49(52(4,5)6)51(66)61-27-36(63)24-43(61)50(65)58-32(2)34-13-15-35(16-14-34)48-33(3)57-30-71-48/h9-16,25-26,30-32,36,43,47,49,59,63H,17-24,27-29H2,1-8H3,(H,58,65)(H,60,64)/t31-,32+,36-,43+,47-,49-/m1/s1",C[C@@H]1CC2=C([C@H](N1CC(C)(C)F)C3=C(C=C(C=C3F)OCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@H](C)C5=CC=C(C=C5)C6=C(N=CS6)C)O)C(C)(C)C)F)NC7=CC=CC=C27,"(2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[3,5-difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide",NULL,Classification|Patents,2,NULL,20190720,AbaChemScene|BindingDB|BLD Pharm|ChEMBL|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,NULL
XCSUEITWRRFFMN-SJQMKIJVSA-N,975,P62942,FKBP12,CRBN,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCOCC3=CN(CCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)N=N3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.27,NA,Degradation of FKBP12 in Jurkat cells after 12 h treatment,NA,NA,10.1038/s41421-018-0079-1,1426.71,1425.757089,5.33,-5.72,102,8,24,4,23,338.41,C75H107N7O20,"InChI=1S/C75H107N7O20/c1-45-17-12-11-13-18-46(2)61(94-8)41-54-24-22-51(7)75(93,102-54)69(87)73(91)81-29-15-14-21-58(81)74(92)101-62(42-59(83)47(3)38-50(6)67(86)68(96-10)66(85)49(5)37-45)48(4)39-52-23-26-60(63(40-52)95-9)100-36-35-99-44-53-43-80(79-78-53)30-32-98-34-33-97-31-28-76-56-20-16-19-55-65(56)72(90)82(71(55)89)57-25-27-64(84)77-70(57)88/h11-13,16-20,38,43,45,47-49,51-52,54,57-58,60-63,67-68,76,86,93H,14-15,21-37,39-42,44H2,1-10H3,(H,77,84,88)/b13-11+,17-12+,46-18+,50-38+/t45-,47-,48-,49-,51-,52+,54+,57?,58+,60-,61+,62+,63-,67-,68+,75-/m1/s1",146026069,Fkbp12 protac RC32,FKBP12 PROTAC RC32|CHEMBL4591678|HY-130835|CS-0114364,1426.7,C75H107N7O20,338,2980,5.8,102,4,23,23,"InChI=1S/C75H107N7O20/c1-45-17-12-11-13-18-46(2)61(94-8)41-54-24-22-51(7)75(93,102-54)69(87)73(91)81-29-15-14-21-58(81)74(92)101-62(42-59(83)47(3)38-50(6)67(86)68(96-10)66(85)49(5)37-45)48(4)39-52-23-26-60(63(40-52)95-9)100-36-35-99-44-53-43-80(79-78-53)30-32-98-34-33-97-31-28-76-56-20-16-19-55-65(56)72(90)82(71(55)89)57-25-27-64(84)77-70(57)88/h11-13,16-20,38,43,45,47-49,51-52,54,57-58,60-63,67-68,76,86,93H,14-15,21-37,39-42,44H2,1-10H3,(H,77,84,88)/b13-11+,17-12+,46-18+,50-38+/t45-,47-,48-,49-,51-,52+,54+",C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCOCC5=CN(N=N5)CCOCCOCCNC6=CC=CC7=C6C(=O)N(C7=O)C8CCC(=O)NC8=O)C)/C)O)OC)C)C)/C)OC,"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-[2-[[1-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethyl]triazol-4-yl]methoxy]ethoxy]-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone",NULL,Classification,1,NULL,20200430,AbaChemScene|ChEMBL|MedChemexpress MCE|MolPort,Chemical Vendors|Curation Efforts|Research and Development,NULL
YNDJPWSVYYRNTJ-MEXKHVBFSA-N,733,P10275,AR,cIAP1,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(=O)NCCOCCOCCOCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,NA,NA,NA,NA,NA,10.1016/j.bmc.2011.09.041,770.021,769.4877307,4.11,-6.06,55,5,10,4,20,175.51,C43H67N3O9,"InChI=1S/C43H67N3O9/c1-28(2)24-36(46-41(51)39(49)35(44)25-29-8-6-5-7-9-29)40(50)45-18-19-52-20-21-53-22-23-54-27-38(48)55-37-13-12-33-32-11-10-30-26-31(47)14-16-42(30,3)34(32)15-17-43(33,37)4/h5-9,28,30,32-37,39,49H,10-27,44H2,1-4H3,(H,45,50)(H,46,51)/t30-,32-,33-,34-,35+,36-,37-,39-,42-,43-/m0/s1",54764407,PROTAC AR Degrader-4,"PROTAC AR Degrader-4|CHEMBL2151741|AKOS037653397|HY-111848|CS-0093246|17beta-[[8-[[N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucyl]amino]-3,6-dioxaoctane-1-yloxy]acetoxy]-5alpha-androstane-3-one",770,C43H67N3O9,176,1280,4.8,55,4,10,21,"InChI=1S/C43H67N3O9/c1-28(2)24-36(46-41(51)39(49)35(44)25-29-8-6-5-7-9-29)40(50)45-18-19-52-20-21-53-22-23-54-27-38(48)55-37-13-12-33-32-11-10-30-26-31(47)14-16-42(30,3)34(32)15-17-43(33,37)4/h5-9,28,30,32-37,39,49H,10-27,44H2,1-4H3,(H,45,50)(H,46,51)/t30-,32-,33-,34-,35+,36-,37-,39-,42-,43-/m0/s1",CC(C)C[C@@H](C(=O)NCCOCCOCCOCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)C4)C)C)NC(=O)[C@H]([C@@H](CC5=CC=CC=C5)N)O,"[(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] 2-[2-[2-[2-[[(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoyl]amino]ethoxy]ethoxy]ethoxy]acetate",NULL,Biological Test Results|Classification,2,690789,20120116,AbaChemScene|AKos Consulting & Solutions|ChEMBL|Japan Chemical Substance Dictionary (Nikkaji)|MedChemexpress MCE|Thomson Pharma,Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,NULL
ZAOSGDCLGNWLSI-ACALULJJSA-N,731,NA,RAR,cIAP1,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(=O)NCCOCCOCCOCC(=O)NCCCOC1=CC(/C=C/C(=O)C2=CC(C(C)(C)C)=CC(C(C)(C)C)=C2)=CC=C1C(=O)O,NA,NA,NA,NA,NA,10.1016/j.bmc.2011.09.041,917.154,916.5197591,2.46,-6.65,66,3,11,6,28,224.84,C51H72N4O11,"InChI=1S/C51H72N4O11/c1-34(2)27-42(55-48(60)46(58)41(52)28-35-13-10-9-11-14-35)47(59)54-20-22-63-23-24-64-25-26-65-33-45(57)53-19-12-21-66-44-29-36(15-17-40(44)49(61)62)16-18-43(56)37-30-38(50(3,4)5)32-39(31-37)51(6,7)8/h9-11,13-18,29-32,34,41-42,46,58H,12,19-28,33,52H2,1-8H3,(H,53,57)(H,54,59)(H,55,60)(H,61,62)/b18-16+/t41-,42+,46+/m1/s1",54764325,PROTAC RAR Degrader-1,PROTAC RAR Degrader-1|CHEMBL2151737|1351169-27-1|AKOS037653375|HY-111844|CS-0093242,917.1,C51H72N4O11,225,1480,4.4,66,6,12,30,"InChI=1S/C51H72N4O11/c1-34(2)27-42(55-48(60)46(58)41(52)28-35-13-10-9-11-14-35)47(59)54-20-22-63-23-24-64-25-26-65-33-45(57)53-19-12-21-66-44-29-36(15-17-40(44)49(61)62)16-18-43(56)37-30-38(50(3,4)5)32-39(31-37)51(6,7)8/h9-11,13-18,29-32,34,41-42,46,58H,12,19-28,33,52H2,1-8H3,(H,53,57)(H,54,59)(H,55,60)(H,61,62)/b18-16+/t41-,42+,46+/m1/s1",CC(C)C[C@@H](C(=O)NCCOCCOCCOCC(=O)NCCCOC1=C(C=CC(=C1)/C=C/C(=O)C2=CC(=CC(=C2)C(C)(C)C)C(C)(C)C)C(=O)O)NC(=O)[C@H]([C@@H](CC3=CC=CC=C3)N)O,"2-[3-[[2-[2-[2-[2-[[(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoyl]amino]ethoxy]ethoxy]ethoxy]acetyl]amino]propoxy]-4-[(E)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid",NULL,Biological Test Results|Classification,2,690792|690794|690795|690796,20120116,AbaChemScene|AKos Consulting & Solutions|BLD Pharm|Chem-Space.com Database|ChEMBL|MedChemexpress MCE|Thomson Pharma,Chemical Vendors|Curation Efforts|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,NULL
